- Home
- AKBA vs JPI Comparison
AKBA vs JPI Comparison
Compare AKBA & JPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- JPI
- Stock Information
- Founded
- AKBA 2007
- JPI 2012
- Country
- AKBA United States
- JPI United States
- Employees
- AKBA N/A
- JPI N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- JPI Finance Companies
- Sector
- AKBA Health Care
- JPI Finance
- Exchange
- AKBA Nasdaq
- JPI Nasdaq
- Market Cap
- AKBA 336.2M
- JPI 289.6M
- IPO Year
- AKBA 2014
- JPI N/A
- Fundamental
- Price
- AKBA $1.83
- JPI $19.74
- Analyst Decision
- AKBA Strong Buy
- JPI
- Analyst Count
- AKBA 1
- JPI 0
- Target Price
- AKBA $7.50
- JPI N/A
- AVG Volume (30 Days)
- AKBA 2.4M
- JPI 54.7K
- Earning Date
- AKBA 11-07-2024
- JPI 01-01-0001
- Dividend Yield
- AKBA N/A
- JPI 6.15%
- EPS Growth
- AKBA N/A
- JPI N/A
- EPS
- AKBA N/A
- JPI N/A
- Revenue
- AKBA $169,879,000.00
- JPI N/A
- Revenue This Year
- AKBA N/A
- JPI N/A
- Revenue Next Year
- AKBA $30.85
- JPI N/A
- P/E Ratio
- AKBA N/A
- JPI N/A
- Revenue Growth
- AKBA N/A
- JPI N/A
- 52 Week Low
- AKBA $0.80
- JPI $16.02
- 52 Week High
- AKBA $2.48
- JPI $19.12
- Technical
- Relative Strength Index (RSI)
- AKBA 46.55
- JPI 30.84
- Support Level
- AKBA $1.74
- JPI $20.28
- Resistance Level
- AKBA $1.90
- JPI $21.09
- Average True Range (ATR)
- AKBA 0.09
- JPI 0.35
- MACD
- AKBA -0.03
- JPI -0.10
- Stochastic Oscillator
- AKBA 20.93
- JPI 15.87
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.